natgillin/translations-raw huggingface dataset:
Dato for åbning:..............
Opening date:
DATO FORFØRSTE MARKEDSFØRINGSTILLADELSE/FORNYELSE AFTILLADELSEN
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
DATO FORÆNDRING AF TEKSTEN
DATE OF REVISION OF THE TEXT
Dato og tidspunkt for behandling Batchnummer og indgivet dosis
Date and time of treatment Batch number and dose received
datoen for indgivelsen,
the date of administration,
Datoen for, hvornår der er gået 6 måneder efter overflytning til stuetemperatur, skal anføres på produktets karton.
Please record the end of the 6 months storage at room temperature on the product carton.
Datoen for, hvornår inhalatoren skal kasseres, skal angives på etiketten i det dertil beregnede felt.
Write the date the inhaler should be discarded on the label in the space provided.
Datoen for, hvornår pakningen med den fyldte injektionssprøjte med ReFacto AF er taget ud af køleskabet og opbevares ved stuetemperatur (op til 25 oC), skal noteres på den ydre karton.
Record on the outer carton the date ReFacto AF pre-filled syringe is removed from the refrigerator and set at room temperature (up to 25oC).
Datoen for, hvornår pakningen med ReFacto AF er taget ud af køleskabet og opbevares ved stuetemperatur (op til 25 oC), skal noteres på den ydre karton.
Record on the outer carton the date ReFacto AF is removed from the refrigerator and set at room temperature (up to 25oC).
Datoen skal skrives på etiketten umiddelbart efter, at inhalatoren er taget ud af bakken.
The date should be added as soon as the inhaler has been removed from the tray.
Datoen ”Kasseres senest” er 6 uger fra den dag, hvor bakken blev åbnet.
The “Discard by” date is 6 weeks from the date you open the tray.
Datoer for behandling med Ranexa: Start………………………
Dates of Ranexa treatment: Start
Datoerne for og resultaterne af graviditetstest
Pregnancy test dates and results
Datoerne for og resultaterne af graviditetstests
Pregnancy test dates and results
DATOS CLÍNICOS
CLINICAL PARTICULARS
DATOS FARMACÉUTICOS
PHARMACEUTICAL PARTICULARS
Datos preclínicos sobre seguridad
Preclinical safety data
DaTSCAN 74 MBq/ml injektionsvæske, opløsning
DaTSCAN 74 MBq/ml solution for injection
DaTSCAN 74 MBq/ml injektionsvæske, opløsning.
DaTSCAN 74 MBq/ml solution for injection
DaTSCAN anbefales ikke til børn i alderen 0 til 18 år
DaTSCAN is not recommended for children aged 0 to 18 years
DaTSCAN benyttes til at skelne mellem en form for demens, der kaldes "Lewy body-demens", og Alzheimers sygdom.
DaTSCAN is used to help distinguish between a type of dementia known as ‘dementia with Lewy bodies’ and Alzheimer’s disease.
DaTSCAN er en 2,5 eller 5 ml injektionsvæske, opløsning, leveret i ét enkelt farveløst 10 ml hætteglas forseglet med en gummilukke og metalforsegling.
DaTSCAN is a 2.5 or 5 ml colourless solution for injection, supplied in a single colourless 10 ml glass vial sealed with a rubber closure and metal overseal.
DaTSCAN er ikke i stand til at differentiere mellem demens med Lewy legemer og demens ved Parkinsons sygdom.
DaTSCAN is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia.
DaTSCAN har ingen kendt indflydelse på evnen til at føre motorkøretøj og betjene maskiner.
DaTSCAN has no known influence on the ability to drive and use machines.
DaTSCAN indeholder det aktive stof ioflupan (123I), der anvendes som hjælp til at identificere (diagnosticere) sygdomme i hjernen.
DaTSCAN contains the active substance ioflupane (123I) which is used to help identify (diagnose) conditions in the brain.
DaTSCAN må ikke bruges hvis De er allergisk over for ioflupan eller et af de øvrige indholdsstoffer i DaTSCAN (angivet i afsnit 6). hvis De er gravid.
if you are allergic to ioflupane or any of the other ingredients of this medicine (listed in section 6). if you are pregnant
DaTSCANS udseende og pakningstørrelse
What DaTSCAN looks like and contents of the pack
DATUM VAN EERSTE VERLENING VAN DE VERGUNNING/VERLENGING VAN DE VERGUNNING
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Datum van eerste verlening van de vergunning: 28 september 2009 Datum van laatste verlenging:
Date of first authorisation: 28/9/2009 Date of latest renewal:
DATUM VAN HERZIENING VAN DE TEKST
DATE OF REVISION OF THE TEXT
DAUN (45 mg/m2/dag bolus, i.v.): dag 1 og 2
DAUN (45 mg/m2/day bolus, IV): days 1 and 2
DAUN (45 mg/m²/dag bolus, i.v.): dag 1 og 2
DAUN (45 mg/m2/day bolus, IV): days 1 and 2
Daunorubicin 30 mg/m² i.v., dag 1-3, 15-16;
Daunorubicin 30 mg/m2 i.v., days 1-3, 15-16; V
Daunorubicin 45 mg/m2 i.v., dag 6-7, 13-14
45 mg/m2 i.v., days 6-7, 13-14
Daunorubicin 45 mg/m2 i.v., dag 6-7, 13-14
Daunorubicin 45 mg/m2 i.v., days 6-7, 13-14
Daunorubicin 45 mg/m² i.v., dag 6-7, 13-14
Daunorubicin 45 mg/m2 i.v., days 6-7, 13-14
Daunorubicin 60 mg/m2 i.v. (1 time), dag 1-3;
Daunorubicin 60 mg/m2 i.v. (1 h), days 1-3;
Daunorubicin 60 mg/m² i.v. (1 time), dag 1-3;
Daunorubicin 60 mg/m2 i.v. (1 h), days 1-3;
daunorubicin, doxorubicin, paclitaxel eller topotecan mod kræft
daunorubicin, doxorubicin, paclitaxel, or topotecan for cancer
daunorubicin, doxorubicin, paclitaxel eller topotecan mod kræft (cancer)
daunorubicin, doxorubicin, paclitaxel, or topotecan for cancer
daunorubicin, doxorubicin, paclitaxel eller topotecan mod kræft (cancer).
Daunorubicin, doxorubicin, paclitaxel, or topotecan for cancer
Daxas 500 mikrogram
Daxas 500 micrograms
Daxas anbefales ikke, hvis du har en eller flere af følgende sygdomme: svære immunologiske sygdomme som HIV-infektion, multipel sklerose (MS), lupus erythematosus (LE) eller progressiv multifokal leukoenkefalopati, (PML)
Daxas is not recommended if you have one or more of the following diseases: severe immunological diseases such as HIV infection, multiple sclerosis (MS), lupus erythematosus (LE) or progressive multifocal leukoencephalopathy (PML)
Daxas anvendes ikke alene, men som tillæg til behandling med bronkodilatorer (lægemidler, som udvider luftvejene i lungerne).
Daxas is not used on its own but as an ‘add-on’ to treatment with bronchodilators (medicines that widen the airways in the lungs).
Daxas anvendes til behandling af svær, kronisk obstruktiv lungesygdom (KOL) hos voksne patienter med kronisk bronkitis (langvarig betændelse i luftvejene), hvis KOL hyppigt blusser op.
Daxas is used to treat severe chronic obstructive pulmonary disease (COPD) in adults who have chronic bronchitis (long-term inflammation of the airways), and whose COPD flares up frequently.
Daxas blev sammenlignet med placebo (en virkningsløs behandling) i to hovedundersøgelser, der omfattede 3 000 voksne med svær KOL, som havde oplevet, at sygdommen var blusset op mindst én gang i løbet af det seneste år.
Daxas has been compared with placebo (a dummy treatment) in two main studies involving over 3,000 adults with severe COPD who had had at least one flare-up of their disease in the past year.
Daxas bør ikke bruges til børn og teenagere under 18 år.
Daxas should not be used by children and adolescents under 18 years of age.
Daxas er et lægemiddel, der indeholder det aktive stof roflumilast.
Daxas is a medicine that contains the active substance roflumilast.
Daxas er ikke indiceret som anfaldsmedicin til lindring af akutte bronkospasmer.
Daxas is not indicated as rescue medicinal product for the relief of acute bronchospasms.
Daxas er undersøgt i kliniske studier i op til et år.
Daxas has been studied in clinical trials for up to one year.
Daxas kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Daxas må ikke anvendes til patienter, der lider af moderate eller svære leversygdomme.
Daxas must not be used in patients who have moderate or severe problems with their liver.
Daxas påvirker ikke arbejdssikkerheden eller evnen til at færdes sikkert i trafikken.
Daxas has no influence on the ability to drive and use machines.
Daxas påvirker ikke evnen til at føre motorkøretøj eller betjene maskiner.
Daxas has no influence on the ability to drive and use machines.
Daxas skal muligvis tages i flere uger for at opnå effekt (se pkt.
Daxas may need to be taken for several weeks to achieve its effect (see section 5.1).
Daxas viste sig at være mere effektivt end placebo til behandling af KOL.
Daxas was shown to be more effective than placebo at treating COPD.
dAXP < 100 nmol/ml efter Strimvelisd
<100 nmol/ml after Strimvelisd n
Day 1: ≥ 1,5 x 109/l
Day 1: ≥1.5 x 109/L
DB-
34.9
DC/alu) blister
blister
DC/alu) blister
blister (PVC/PE/PVDC/alu)
DCarbH
DCarbH (n=1074)
DCR (komplet respons, partielt respons eller stabil sygdom) var signifikant højere hos patienter, som blev behandlet med Lonsurf (44% versus 16%, p < 0,0001).
The DCR (complete response or partial response or stable disease) was significantly higher in patients treated with Lonsurf (44% vs 16%, p < 0.0001).
DD måned ÅÅÅÅ}
DD month YYYY
DD. måned ÅÅÅÅ
{DD month YYYY}
DD/MM/ÅÅÅÅ
12/03/2014
DD/MM/ÅÅÅÅ
DD/ MM/YYYY
dd/mm/åååå
{DD/MM/YYYY}
DDI er ikke undersøgt
DDI not studied
ddI+d4T (fastende)
ddI+d4T (fasted)
De
. They
De "høje" doser Zypadhera var mere effektive til at forebygge en forværring af symptomerne end den "lave" dosis.
The ‘high’ doses of Zypadhera were more effective at preventing a worsening of symptoms than the ‘low’ dose.
De 1- årige (74 %) og 2-årige (51 %) estimater for samlet overlevelse for kombinationsarmen var større end for dabrafenib-monoterapi-armen (henholdsvis 68 % og 42 %).
The 1-year (74%) and 2-year (51%) OS estimates for the combination arm were greater than those for dabrafenib monotherapy (68% and 42% respectively).
De 1-årige (74 %) og 2-årige (51 %) estimater for samlet overlevelse for kombinationsarmen var større end for dabrafenib-monoterapi-armen (henholdsvis 68 % og 42 %).
The 1-year (74%) and 2-year (51%) OS estimates for the combination arm were greater than those for dabrafenib monotherapy (68% and 42% respectively).
De 10 kapsler lægges i inhalatoren en ad gangen.
Each of the ten capsules is put into the inhaler one at a time.
De 10 mg filmovertrukne tabletter er hvide til off-white, kapselformede (12,5 x 5,6 mm), bikonvekse tabletter med en delekærv på den ene side og præget med ”10” på den anden side.
The 10 mg film-coated tablets are white to off-white, capsule shaped (12.5 x 5.6 mm), biconvex tablets with a break score on one side and embossed with “10” on the other side.
De 1483 patienter, som indgik i den primære analyse, havde en gennemsnitsalder på 43 år (interval 17- 80 år), 86% var mænd, 75% var hvide, 13% var sorte og 1% var asiatiske.
The 1483 patients included in the primary analysis had a median age of 43 years (range 17-80), were 86% male, 75% white, 13% black and 1% Asian.
De 15 mg filmovertrukne tabletter er hvide til off-white, kapselformede (14,0 x 6,0 mm), bikonvekse tabletter, glatte på den ene side og præget med ”15” på den anden side.
The 15 mg film-coated tablets are white to off-white, capsule shaped (14.0 x 6.0 mm), biconvex tablets plain on one side and embossed with “15” on the other side.
De 199 randomiserede patienter havde en gennemsnitsalder på 58 år, 64 % var mænd, 68 % var kaukasere, og alle patienterne havde baseline ECOG Performance Status (PS) på 0 eller 1.
Of the 199 randomized patients, the mean age was 58 years, 64% were male, 68% were Caucasian, and all patients had baseline ECOG Performance Status (PS) of 0 or 1.
De 2 aktive stoffer supplerer hinanden med at kontrollere blodsukkeret hos voksne patienter med type 2-diabetes mellitus.
The two active substances work together to control blood sugar levels in adult patients with a form of diabetes called ‘type 2 diabetes mellitus’.
De 2 behandlingsgrupper var godt afbalanceret i forhold til baseline-karakteristika og sygdomsstatus.
The two treatment groups were well balanced in baseline disease characteristics and disease status.
De 2 behandlingsgrupper var ligeligt fordelt med hensyn til baseline-karakteristika og sygdomsstatus.
The two treatment groups were well balanced with regard to baseline characteristics and disease status.
De 2 behandlingsgrupper var sammenlignelige, hvad angår den samlede forekomst af alle grader af blødningshændelser (6,3% i BR- CAP-gruppen og 5,0% i R-CHOP-gruppen) såvel som blødningshændelser grad 3 og højere (BR-CAP: 4 patienter [1,7%]; R-CHOP: 3 patienter [1,2%]).
The two treatment groups were similar with regard to the overall incidence of all-grade bleeding events (6.3% in the BR-CAP group and 5.0% in the R-CHOP group) as well as Grade 3 and higher bleeding events (BR-CAP: 4 patients [1.7%]; R-CHOP: 3 patients [1.2%]).
De 2 behandlingsgrupper var velbalancerede i forhold til baseline- karakteristika og sygdomsstatus.
The two treatment groups were well balanced with regards to baseline characteristics and disease status.
De 2 bivirkninger, som blev rapporteret, var influenzalignende symptomer ved en dosis på 1,8 g rituximab og letalt respirationssvigt ved en dosis på 2 g rituximab.
The two adverse events that were reported were flu-like symptoms, with a dose of 1.8 g of rituximab and fatal respiratory failure, with a dose of 2 g of rituximab.
De 2 dele af den orale doseringssprøjte og medicinbægret skal vaskes med varmt vand og lufttørres.
Wash both parts of the oral dosing syringe and the medicine cup with warm water and air dry.
De 2 fase 3-studier ekskluderede patienter med ukontrolleret hypertension, klinisk signifikant hjertesygdom udtrykt som myokardieinfarkt, arterielle trombotiske hændelser i de seneste 6 måneder, svær eller ustabil angina pectoris, NYHA-klasse III eller IV hjerteinsufficiens (studie 301) eller klasse II til IV hjerteinsufficiens (studie 302) eller uddrivningsfraktion < 50 %.
Both phase 3 studiesexcluded patients with uncontrolled hypertension, clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or NYHA Class III or IV heart failure (study 301) or Class II to IV heart failure (study 302) or cardiac ejection fraction measurement of < 50%.
De 2 primære effektparametre var progressionsfri overlevelse og OS.
The co-primary outcome measures were progression-free survival and OS.
De 2,3 ml solvens skal trækkes op fra hætteglasset med solvens, som er sat direkte på en 3-ml sprøjte, og skal derefter injiceres i hætteglasset med pulver til rekonstitution med en 27-gauge, ½-inch kanyle (for at opnå et endeligt rekonstitutionsvolumen på 2,75 ml).
The 2.3 ml of solvent should be withdrawn from the solvent vial attached directly to a 3 ml syringe and then injected into the powder vial for reconstitution using the 27 gauge, ½-inch needle (to obtain a final reconstitution volume of 2.75 ml).
De 20 mg filmovertrukne tabletter er hvide til off-white, kapselformede (15,6 x 8,0 mm), bikonvekse tabletter med en delekærv på den ene side og præget med ”20” på den anden side.
The 20 mg film-coated tablets are white to off-white, capsule shaped (15.6 x 8.0 mm), biconvex tablets with a break score on one side and embossed with “20” on the other side.
De 20 mg filmovertrukne tabletter er hvide til off-white, kapselformede (15,6 x 8,6 mm), bikonvekse tabletter med en delekærv på den ene side og præget med ”20” på den anden side.
The 20 mg film-coated tablets are white to off-white, capsule shaped (15.6 x 8.0 mm), biconvex tablets with a break score on one side and embossed with “20” on the other side.
De 219 patienter med sår på donorstedet for delhudstransplantater var i gennemsnit 53 år, og størrelsen af såret på donorstedet var i gennemsnit 81,5 cm2.
The 219 patients with split-thickness skin graft donor site wounds had a mean age of 53 years; their donor site mean wound size was 81.5 cm2.
De 28 dage kaldes en ’behandlingscyklus’.
Each 28 days is called a ‘treatment cycle’.
De 30 beholdere i pakken skal skilles fra hinanden og sættes ned i de nummererede pladser, begyndende med den plads, der er forsynet med dags dato.
The 30 vials in the pack should be separated from each other and fitted into the numbered spaces starting with the space that is numbered with today’s date.
De 36 patienter havde en median alder på 14,5 år, og 55,6 % var piger, 88,9 % var sorte og 11,1 % var asiater.
The 36 patients had a median age of 14.5 years and were 55.6% female, 88.9% Black, and 11.1% Asian.
De 4 gule tabletter er inaktive tabletter, der ikke indeholder hormoner og som kaldes placebo- tabletter.
The 4 yellow tablets are inactive tablets that do not contain hormones and are called placebo tablets.
De 4 gule tabletter er inaktive tabletter, der ikke indeholder hormoner, og som kaldes placebo- tabletter.
The 4 yellow tablets are inactive tablets that do not contain hormones and are called placebo tablets.
De 4,0 ml koncentratopløsning skal injiceres i en 500 ml pose/flaske med skylleopløsning.
4.0 mL of concentrate solution should be injected into a 500 mL bag /bottle of irrigation solution.
De 5 mg filmovertrukne tabletter er hvide til off-white, kapselformede (9,6 x 4,54 mm), bikonvekse tabletter, glatte på den ene side og præget med ”5” på den anden side.
The 5 mg film-coated tablets are white to off-white, capsule shaped (9.6 x 4.54 mm), biconvex tablets plain on one side and embossed with “5” on the other side.
De 5 patienter, som døde på grund af sepsis (4 på grund af urinvejsinfektion og en yderligere på grund af liggesår), havde alle fremskreden multipel sklerose og fik flere medicinske behandlinger.
The 5 patients who died due to sepsis (4 due to urinary tract infection and 1 secondary to decubitus ulcers), all had advanced Multiple Sclerosis disease and multiple drug therapy.
De 50 % effektive koncentrationsværdier (EC50) for emtricitabin var i intervallet fra 0,0013 til 0,64 µM. Emtricitabin viste antiviral aktivitet i cellekultur mod hiv 1 undertype A, B, C, D, E, F og G (EC50-værdier var i intervallet fra 0,007 til 0,075 µM) og viste aktivitet mod hiv 2 (EC50-værdier var i intervallet fra
The 50% effective concentration (EC50) values for emtricitabine were in the range of 0.0013 to 0.64 µM. Emtricitabine displayed antiviral activity in cell culture against HIV-1 subtype A, B, C, D, E, F, and G (EC50 values ranged from 0.007 to 0.075 µM) and showed activity against HIV-2 (EC50 values ranged from 0.007 to
De 63 inkluderede patienter havde en medianalder på 51 år (24 til 68 år, heraf 2% over 65 år); 54% var mænd; 43% havde BMI ≥ 30 kg/m2; median HCV-RNA ved baseline var 6,01 log10 IE/ml; 37% havde cirrose; 30% havde HCV- genotype 4a, og 56% HCV-genotype 4c eller 4d; 79% havde non-CC IL28B-alleler (CT eller TT); 52% var behandlingsnaive, og 48% var behandlingserfarne.
The 63 enrolled patients had a median age of 51 years (range 24 to 68 years; with 2% above 65 years); 54% were male; 43% had a BMI ≥ 30 kg/m2; the median baseline HCV RNA level was 6.01 log10 IU/ml; 37% had cirrhosis; 30% had HCV genotype 4a, and 56% HCV genotype 4c or 4d; 79% had non-CC IL28B alleles (CT or TT); 52% were treatment-naïve, and 48% were treatment-experienced.
De actieve metaboliet van clopidogrel remt selectief de binding van adenosinedifosfaat (ADP) aan de P2Y12-receptor op de trombocyt en de daaropvolgende ADP-gemedieerde activering van het glycoproteïne GPIIb/IIIa- complex, waardoor de bloedplaatjesaggregatie wordt geremd.
The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
De actieve metaboliet wordt voornamelijk gevormd door CYP2C19 met bijdragen van diverse andere CYP-enzymen, waaronder CYP1A2, CYP2B6 en CYP3A4.
The active metabolite is formed mostly by CYP2C19 with contributions from several other CYP enzymes, including CYP1A2, CYP2B6 and CYP3A4.
De ACTIVE-A studie includeerde patiënten die geen behandeling met VKA konden krijgen omdat ze niet in staat waren of niet bereid waren om de behandeling te krijgen.
The ACTIVE-A study included patients who could not receive VKA therapy because they were unable or unwilling to receive the treatment.
De ACTIVE-W studie toonde aan dat de behandeling met vitamine K-antagonisten effectiever was dan de behandeling met clopidogrel en ASA.
The ACTIVE-W study demonstrated that anticoagulant treatment with vitamin K antagonists was more effective than with clopidogrel and ASA.
De acuerdo con las conclusiones científicas para Siklos, el CHMP considera que el balance beneficio-riesgo del medicamento que contiene el principio activo HIDROXICARBAMIDA es favorable sujeto a los cambios propuestos en la información del producto.
On the basis of the scientific conclusions for Siklos, the CHMP is of the opinion that the benefit- risk balance of the medicinal product containing the active substance HYDROXYCARBAMIDE is favourable subject to the proposed changes to the product information.
De af apoteket fyldte sprøjter med hætte, indeholdende fortyndet IL-2, skal opbevares i køleskab (ved 2°C – 8°C) indtil brug.
Store pre-filled, capped syringes of diluted IL-2 dispensed by the pharmacist in the refrigerator (at 2°C – 8°C) until use.
De afname was geassocieerd met een vermindering van 39% (oplaaddosis) en 21% (onderhoudsdosis) van de remming van de plaatjesaggregatie.
The decrease was associated with a 39% (loading dose) and 21% (maintenance dose) reduction of inhibition of platelet aggregation.
De aktive indholdsstoffer er:
The active substances are:
de aktive stoffer
The active substances,
De aktive stoffer elvitegravir, cobicistat og tenofovirdisoproxilfumarat nedbrydes ikke i miljøet.
The active substances elvitegravir, cobicistat and tenofovir disoproxil fumarate are persistent in the environment.
De aktive stoffer er adsorberede, hvilket vil sige, at de er bundet til aluminiumsforbindelser, og vaccinen indeholder en adjuvans, der er et stof, som indeholder aluminium, for at fremme en bedre reaktion.
The active substances are ‘adsorbed’, meaning that they are fixed onto aluminium compounds, and the vaccine contains an ‘adjuvant’ (a compound containing aluminium) to stimulate a better response.
De aktive stoffer er følgende:
The active ingredients are as follows:
De aktive stoffer er indacaterol (som maleat) og glycopyrroniumbromid.
The active substances are indacaterol (as maleate) and glycopyrronium bromide.
De aktive stoffer er lamivudin 150 mg og zidovudin 300 mg.
The active substances are lamivudine 150 mg and zidovudine 300 mg.
De aktive stoffer er lidocain 150 mg/ml og prilocain 50 mg/ml.
The active substances are lidocaine 150 mg/ml and prilocaine 50 mg/ml.
De aktive stoffer er sacubitril og valsartan.
The active substances are sacubitril and valsartan.
De aktive stoffer er:
The active substances are:
De aktive stoffer er: norelgestromin og ethinylestradiol.
The active substances are norelgestromin and ethinyl estradiol.
De aktive stoffer i Anoro, umeclidinium og vilanterol, udvider luftvejene og forbedrer vejrtrækningen ved KOL, men de virker på hver sin måde.
The active substances in Anoro, umeclidinium and vilanterol, work in different ways to widen the airways and improve breathing in COPD.
De aktive stoffer i Certifect fungerer som ektoparasitære midler.
The active substances in Certifect act as ‘ectoparasiticides’.
De aktive stoffer i Dutrebis fås i forvejen i Den Europæiske Union (EU) som lægemidler med kun et enkelt aktivt stof: lamivudin som Epivir siden 1996, og raltegravir som Isentress siden 2007.
The active substances in Dutrebis are already available in the European Union (EU) as single- component medicines: lamivudine as Epivir since 1996, and raltegravir as Isentress since 2007.
De aktive stoffer i Evra er to hormoner ethinylestradiol (et østrogen) og norelgestromin (et progestogen).
The active substances in Evra are two hormones, ethinyl estradiol (an oestrogen) and norelgestromin (a progestogen).
De aktive stoffer i Icandra, vildagliptin og metformin, tilhører en gruppe lægemidler, der kaldes ”orale antidiabetika”.
The active substances of Icandra, vildagliptin and metformin, belong to a group of medicines called “oral antidiabetics”.